Literature DB >> 32310047

MicroRNA: Promising Roles in Cancer Therapy.

Atieh Hashemi1, Gilar Gorji-Bahri1.   

Abstract

BACKGROUND: MicroRNAs (miRNA) are small non-coding RNAs that act as one of the main regulators of gene expression. They are involved in maintaining a proper balance of diverse processes including differentiation, proliferation and cell death in normal cells. Cancer biology can also be affected by these molecules by modulating the expression of oncogenes or tumor suppressor genes. Thus, miRNA based anticancer therapy is currently being developed either alone or in combination with chemotherapy agents used in cancer management, aiming at promoting tumor regression and increasing cure rate. Access to large quantities of RNA agents can facilitate RNA research and development. In addition to currently used in vitro methods, fermentation-based approaches have recently been developed which can cost-effectively produce biological RNA agents with proper folding needed for the development of RNA-based therapeutics. Nevertheless, a major challenge in translating preclinical studies to clinical for miRNA-based cancer therapy is the efficient delivery of these agents to target cells. Targeting of miRNAs/antimiRNAs using antibodies and/or peptides can minimize cellular and systemic toxicity.
CONCLUSION: Here, we provide a brief review of miRNA in the following aspects: biogenesis and mechanism of action of miRNAs, the role of miRNAs in cancer as tumor suppressors or oncogenes, the potential of using miRNAs as novel and promising therapeutics, miRNA-mediated chemo-sensitization, and currently utilized methods for the in vitro and in vivo production of RNA agents. Finally, an update on the viral and non-viral delivery systems is addressed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Bioengineered non-coding RNA agent; Biogenesis; Cancer; Chemo-Sensitization; Deliveryzzm321990Systemszzm321990; MicroRNAs; Oncomirs

Year:  2020        PMID: 32310047     DOI: 10.2174/1389201021666200420101613

Source DB:  PubMed          Journal:  Curr Pharm Biotechnol        ISSN: 1389-2010            Impact factor:   2.837


  7 in total

Review 1.  MicroRNAs and Corresponding Targets in Esophageal Cancer as Shown In Vitro and In Vivo in Preclinical Models.

Authors:  Ulrich H Weidle; Adam Nopora
Journal:  Cancer Genomics Proteomics       Date:  2022 Mar-Apr       Impact factor: 4.069

Review 2.  Emerging urinary alpha-synuclein and miRNA biomarkers in Parkinson's disease.

Authors:  Banabihari Giri; Marissa Seamon; Aditi Banerjee; Sneha Chauhan; Sharad Purohit; John Morgan; Babak Baban; Chandramohan Wakade
Journal:  Metab Brain Dis       Date:  2021-04-21       Impact factor: 3.655

3.  MicroRNA-377-3p targeting MMP-16 inhibits ovarian cancer cell growth, invasion, and interstitial transition.

Authors:  Huabin Wang; Changmin Qi; Dan Wan
Journal:  Ann Transl Med       Date:  2021-01

Review 4.  Polyethyleneimine-Based Lipopolyplexes as Carriers in Anticancer Gene Therapies.

Authors:  Julia Jerzykiewicz; Aleksander Czogalla
Journal:  Materials (Basel)       Date:  2021-12-27       Impact factor: 3.623

5.  Therapeutic miR-506-3p Replacement in Pancreatic Carcinoma Leads to Multiple Effects including Autophagy, Apoptosis, Senescence, and Mitochondrial Alterations In Vitro and In Vivo.

Authors:  Hannes Borchardt; Alexander Kogel; Hermann Kalwa; Ulrike Weirauch; Achim Aigner
Journal:  Biomedicines       Date:  2022-07-13

6.  Repetitive Sequence Transcription in Breast Cancer.

Authors:  Walter Arancio; Claudia Coronnello
Journal:  Cells       Date:  2022-08-14       Impact factor: 7.666

7.  A panel of miRNAs as prognostic markers for African-American patients with triple negative breast cancer.

Authors:  Safaa Turkistani; Bruna M Sugita; Paolo Fadda; Rafael Marchi; Ali Afsari; Tammey Naab; Victor Apprey; Robert L Copeland; Michael C Campbell; Luciane R Cavalli; Yasmine Kanaan
Journal:  BMC Cancer       Date:  2021-07-27       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.